Can Older Cancer Patients Tolerate Chemotherapy? BACKGROUND. To the authors knowledge, few data currently are available regarding
|
|
- Shannon Hancock
- 5 years ago
- Views:
Transcription
1 1107 Can Older Cancer Patients Tolerate Chemotherapy? A Prospective Pilot Study Hongbin Chen, M.D., Ph.D. Alan Cantor, Ph.D. Julie Meyer, A.R.N.P., M.P.H. Mary Beth Corcoran, R.Ph. Edward Grendys, M.D. Denise Cavanaugh, R.N. Shirley Antonek, C.C.R.P. Angela Camarata, C.C.R.P. William Haley, Ph.D. Lodovico Balducci, M.D. Martine Extermann, M.D., Ph.D. Senior Adult Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida. Supported in part by a grant from the American Cancer Society (IRG no. 32). Address for reprints: Martine Extermann, M.D., Ph.D., Senior Adult Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Magnolia Drive, Tampa, FL 33612; Fax: (813) ; extermann@moffitt.usf.edu Received June 14, 2002; revision received September 5, 2002; accepted September 27, BACKGROUND. To the authors knowledge, few data currently are available regarding the tolerance to chemotherapy in older cancer patients. This prospective pilot study evaluated the changes in functional, mental, nutritional, and comorbid status, as well as the quality of life (QOL), in geriatric oncology patients receiving chemotherapy. METHODS. Sixty patients age 70 years who were undergoing cancer chemotherapy were recruited in a university-based comprehensive cancer center. Changes in physical function were measured by the Eastern Cooperative Oncology Group performance status (ECOG PS) and Instrumental Activities of Daily Living (IADLs), mental health changes were measured by the Mini-Mental State Examination and the Geriatric Depression Scale (GDS), comorbidity was measured by Charlson s index and the Cumulative Illness Rating Scale-Geriatric, nutrition was measured by the Mini-Nutritional Assessment, and QOL was measured by the Functional Assessment of Cancer Therapy-General (FACT-G). Changes were assessed at baseline and at the end of treatment (EOT). Grade 4 hematologic and Grade 3 4 nonhematologic toxicities were recorded. RESULTS. Thirty-seven patients (63%) completed both assessments. Older cancer patients demonstrated a significant decline in measurements of physical function after receiving chemotherapy, as indicated by changes in scores on the IADL (P 0.04) and on the physical (P 0.01) and functional (P 0.03) subscales of the FACT-G. They also displayed worse scores on the GDS administered postchemotherapy (P 0.01). Patients who experienced severe chemotoxicity had more significant declines in ECOG PS (P 0.03), IADL (P 0.03), and GDS (P 0.04), and more gain in the social well-being subscale (P 0.02) of the FACT-G, than those who did not experience severe chemotoxicity. However, changes in most scores were small in magnitude clinically. No significant change was found between baseline and EOT in nutrition, comorbidity, and other aspects of the FACT-G. CONCLUSIONS. Older cancer patients undergoing chemotherapy may experience toxicity but generally can tolerate it with limited impact on independence, comorbidity, and QOL levels. It is important to recognize and monitor these changes during geriatric oncology treatment. Cancer 2003;97: American Cancer Society. DOI /cncr KEYWORDS: aged, cancer, chemotherapy, comprehensive geriatric assessment, quality of life. Nearly 60% of all incident cancers and 70% of all cancer mortalities occur in the 65-year-and-older age group. 1 Yet, studies of patterns of care in geriatric oncology patients have shown mixed, sometimes discouraging, results. The evidence suggests that the choice of cancer therapy varied with the age of patient. 2 7 Older people were less likely 2003 American Cancer Society
2 1108 CANCER February 15, 2003 / Volume 97 / Number 4 to receive treatments that were considered definitive or potentially curative than younger patients, regardless of cancer site or stage at diagnosis Whereas chronologic age is not often cited by physicians as a reason for not recommending aggressive therapy, other age-related factors such as the presence of comorbid conditions and functional disability were independent predictors for receiving less standard treatment in older cancer patients. 3,4,11,12 Clinicians may be legitimately concerned and thus hesitant to pursue, for instance, chemotherapy because of the existence of these factors that could potentially complicate cancer treatment or recovery in an older patient. 13 In addition, treatment decision-making could also be influenced by the oncologist s knowledge about the efficacy of a specific cancer treatment such as chemotherapy among older patients and the uncertainty of the safety of such treatment. 14 However, it has been documented that older cancer patients could still benefit from chemotherapy and tolerate the side effects with appropriate dose modification and timely management However, few data are available regarding the tolerance to chemotherapy among geriatric oncology patients in terms of changes in functional, mental, nutritional, comorbid status, and quality of life (QOL), which are not traditional end points in cancer treatment research. The current study was part of a prospective pilot study that evaluated predictors of toxicity from chemotherapy in older cancer patients. 20 We evaluated the effect of chemotherapy, in particular chemotherapy-related toxicity, on physical function, mental health, nutrition, comorbidity, and QOL in older cancer patients. Previous studies have shown that functional disability and comorbidity were common among senior adult oncology patients. 21,22 A multidimensional comprehensive geriatric assessment (CGA) provides valuable information regarding the medical and psychosocial aspects of a patient undergoing cancer treatment. 23 By documenting the changes in these aspects, we would be better able to understand how chemotherapy may affect the life and tolerance level of elderly patients, who are sometimes undertreated. This information can help us to provide optimal cancer therapy and adequate supportive care to older people who undergo chemotherapy. MATERIALS AND METHODS Study Design Sixty patients age 70 years who were treated for cancer in the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida (Tampa, FL) participated in this prospective study between 1998 and They received a standard chemotherapy regimen for a solid tumor or a nonleukemic hematologic malignancy, without concomitant radiation therapy. Any stage of disease and any line of treatment were accepted. Patients in Phase I studies and those receiving myelosuppressive chemotherapy (e.g., for acute leukemia) were not eligible. Patients were evaluated by a research nurse before initiation of chemotherapy (baseline) and at the end of treatment (EOT). The EOT assessment was administered one cycle after the patient finished the last chemotherapy cycle. When the treatment was longer than 6 months, EOT assessment was truncated at 6 months to minimize the influence of outliers. The study was approved by the institutional review board of the University of South Florida. Informed consent was obtained from all study participants. Measurements Patients demographic and clinical characteristics were collected from their medical charts. Chemotherapy toxicities were recorded using the National Cancer Institute/World Health Organization toxicity scale. Severe side effects included Grade 4 hematologic and Grade 3 4 nonhematologic toxicities. In most protocols, these are dose-limiting toxicities that prompt a delay in treatment, a reduction in dosage, or a cessation of treatment. Alopecia was not counted. Tumor responses to the chemotherapy/adjuvant treatment were recorded as disease progression, or as a stable, partial, or complete response. The CGA evaluates the functional, mental, nutritional, comorbid status, and the QOL of a patient. Physical function was measured by the Eastern Cooperative Oncology Group performance status (ECOG PS) and by the Instrumental Activities of Daily Living (IADL). Scores on the ECOG PS range from 0 (fully independent) to 4 (totally bedridden) 24 and scores on the IADL range from 10 to 29 (the higher the score, the better the functional status). 25 Mental health was measured by the Mini-Mental State Examination (MMSE) and by the Geriatric Depression Scale (GDS) short form with scores ranging from 0 to 30 (the higher the score on the MMSE, the better the cognition) 26 and from 0 to 15 (a score of 5 or above on the GDS indicates a high risk of depression). 27 Nutrition was measured by the Mini-Nutritional Assessment (MNA) with scores ranging from 0 to 30 (a score of 23 or below indicates a high risk of malnutrition). 28 Comorbidity was measured by Charlson s index and the Cumulative Illness Rating Scale-Geriatric (CIRS-G). Scores on the Charlson s index range from 0 (no comorbidity) to and possible scores on the CIRS-G range from 0 (no comorbidity) to Patient s QOL was measured by the 34-item Functional Assessment of Cancer Ther-
3 Chemotherapy in Older Patients/Chen et al apy-general (FACT-G, Version 3.0), 31 which contains five subscales: physical, social/family, emotional and functional well-being, and relationship with doctor. Total scores on the FACT-G range from 0 to 136 (highest QOL). Analyses Descriptive data on patients demographic and clinical characteristics were assessed. Student t tests for paired data were used to evaluate the changes in CGA measurements between baseline and EOT. In addition, changes in CGA scores between patients who experienced severe chemotoxicities (Grade 4 hematologic and/or Grade 3 4 nonhematologic toxicities) and those who did not experience such chemotoxicities were compared using repeated measures of analysis of covariance (ANCOVA) with time as a repeated measure at baseline and EOT. The analysis was adjusted for patients age and the dose intensity and toxicity potential of the chemotherapy regimens as covariates. Dose intensity was calculated as the percentage of the planned dosage of chemotherapy. 32 The toxicity potential of each chemotherapy regimen was calculated empirically with the MAX2 index at the beginning of this study (i.e., before the analysis of the data) as a means to compare the published toxicity of various chemotherapy regimens with low or moderate toxicity. The MAX2 index was used as a covariate in the ANCOVA and its construction has been published in detail elsewhere. 20 Finally, changes in scores of CGA measurements among patients with different tumor responses were compared using the analysis of variance. All analyses were performed using SPSS software (version ) (SPSS, Chicago, IL). RESULTS One of the 60 patients who entered the study died before the initiation of chemotherapy. Of the remaining 59 patients, 37 patients (62.7%) completed both the baseline and EOT assessments and were eligible for evaluation of changes in CGA measurements (except for the FACT-G, which was completed by 34 of these 37 patients at EOT). All patients completed the chemotherapy regimens within 6 months, except for one patient who continued to receive capecitabine beyond 6 months. Of the 22 patients who did not complete the EOT assessment, 2 refused, 1 had surgery, 2 had radiation therapy, 5 were transferred to another hospital or hospice, 3 died after starting chemotherapy, and 9 did not return the questionnaires or lost contact. Baseline CGA measurements and other aspects were not significantly different between the 37 patients who completed the EOT assessment and the 23 patients who did not, except that the former scored TABLE 1 Patients Characteristics (n 37) Characteristic Age (yrs) Gender Female 21 Ethnicity White 36 Married 29 Cancer diagnosis Breast 8 Lung a 6 Colorectal 4 Non-Hodgkin lymphoma 4 Ovarian 4 Prostate a 4 Uterine 2 Other genitourinary 2 Other gastrointestinal 2 Malignant melanoma 1 Multiple myeloma 1 Previous treatment 30 Surgery 22 Chemotherapy 10 Radiation 9 Hormone 7 Chemotherapy regimens received Carboplatin-paclitaxel 6 Doxorubicin and cyclophosphamide with/without paclitaxel 5 CHOP with/without rituximab 4 5-FU and leucovorin 3 Gemcitabine and vinorelbine 3 Mitoxantrone and prednisone with/without VX Cisplatin and paclitaxel 2 Docetaxel 2 Irinotecan 2 Gemcitabine 1 Carboplatin and etoposide 1 Other 5 No. of patients CHOP: cyclophosphamide, doxorubin, vincristine, and prednisone; 5-FU: 5-flourouracil; VX 710; a P-glycoprotein inhibitor. a One patient had concurrent lung and prostate carcinoma. higher on the emotional well-being subscale of FACT- G than the latter (16.5 vs. 14.6, P 0.02). Table 1 shows the characteristics of the study patients. The average age of the 37 evaluable patients was 75.6 years (range, 70 87). Fourteen percent of them were 80 years and older. All but one patient were white, greater than one-half (56.8%) were females, and the majority (78.4%) were married. At baseline, 24 patients (65%) had an ECOG PS score of 0 and 10 (27%) scored 1 point. Patients were diagnosed with a variety of cancers, with 21 (56.8%) of them at a metastatic stage. Thirty patients (81%) had received cancer
4 1110 CANCER February 15, 2003 / Volume 97 / Number 4 TABLE 2 Changes in CGA Scores after Receiving Chemotherapy (n 37) CGA Baseline EOT Changes P value ECOG PS IADL MMSE GDS MNA Charlson index CIRS-G Total score Total category FACT-G a Total score Physical Social Emotion Function Relationship CGA: comprehensive geriatric assessment; CIRS-G; Cumulative Illness Rating Scale-Geriatric; ECOG PS: Eastern Cooperative Oncology Group performance status; EOT: end of treatment; FACT-G: Functional Assessment of Cancer Therapy-General; GDS: Geriatric Depression Scale; IADL: Instrumental Activities of Daily Living; MMSE: Mini-Mental State Examination; MNA: Mini-Nutritional Assessment. a Functional Assessment of Cancer Therapy-General (FACT-G) scores were available from 34 patients at both end points. treatment before they started chemotherapy in this study. The chemotherapy regimens prescribed for the patients reflected the wide variety of cancers treated. The median dose intensity received was 95% (range, %) of the planned dose. Greater than one-half of the patients (n 19) experienced severe side effects from the chemotherapy. Fifteen patients (40.5%) had Grade 3 4 nonhematologic and nine (24.3%) had Grade 4 hematologic toxicities. Table 2 shows the CGA scores before and after the patients received chemotherapy. Function-wise, a significant decline in IADL scores, an average of 1.44 points, was found. This corresponds to a significant decline in the subscale scores of physical and functional well-being in the FACT-G measurement of QOL. No significant change was observed in scores on the ECOG PS, MMSE, nutrition, comorbidity, or FACT-G total and other subscales. The distribution of the changes in CGA scores is illustrated in Figure 1. Greater than one-half of the patients had lower scores on the IADL, GDS, MNA, and the physical and functional subscales of FACT-G after receiving chemotherapy treatment. Most patients had no score changes on the ECOG PS and relationship with physicians scores. For example, 90% of patients scored 0 1 on the ECOG PS at baseline. At EOT, that number decreased slightly to 86%. It is noteworthy that a substantial number of patients even had score improvement in the social and emotional subscales of the FACT-G. Changes in CGA scores were compared between patients who experienced severe side effects from chemotherapy and those who did not. Table 3 lists CGA variables that showed significant Group Time differences using repeated measures of ANCOVA. Patients who had severe chemotoxicities had lower physical function scores, as indicated by changes in the ECOG PS and IADL scores, compared with patients who did not have severe chemotoxicities during the treatment. In addition, patients with severe side effects also showed a more significant decline in GDS scores than those without severe side effects. However, their scores on the social well-being subscale of the FACT-G achieved a significant improvement at EOT. Patients with severe chemotoxicities scored 4 points higher at EOT than at baseline on the FACT-G social/family subscale, compared with a 0.84 point decline in that score among patients who did not experience severe chemotoxicities. Although patients without severe side effects had more declines in changes of FACT-G total scores compared with those who experienced severe side effects ( 6.48 vs. 0.74), the difference was not statistically significant (P 0.32). Of the 37 patients who received various chemotherapy regimens, 13 (35%) achieved partial or complete responses, 9 had stable disease, and 7 had cancer progression, whereas 7 (19%) patients received adjuvant chemotherapy. Changes in CGA scores were also compared among patients with different tumor responses to chemotherapy treatment. For the FACT-G total score and the emotional and functional subscale scores, patients with progression of tumor or stable disease showed significant declines. Conversely, pa-
5 Chemotherapy in Older Patients/Chen et al FIGURE 1. Distribution of changes in comprehensive geriatric assessment scores after chemotherapy (%). Black bars: declined; shaded bars: no change; open bars: improved. TABLE 3. Significant Changes in CGA Scores as a Function of Severe Chemotoxicity Occurrence and Time of Measurement (Adjusted for Age; Dose Intensity, and Toxicity Levels of Different Chemotherapy Regimens) CGA With chemotoxicity (n 18) Without chemotoxicity (n 19) Baseline EOT Changes Baseline EOT Changes P value (interaction) ECOG PS IADL GDS FACT-G a Social CGA: comprehensive geriatric assessment; ECOG PS: Eastern Cooperative Oncology Group performance status; EOT: end of treatment; FACT-G: Functional Assessment of Cancer Therapy-General; GDS: Geriatric Depression Scale; IADL: Instrumental Activities of Daily Living. a FACT-G Functional Assessment of Cancer Therapy - General (FACT-G) scores were available from 34 patients (16 with chemotoxicity and 18 without chemotoxicity). tients with partial or complete responses showed improved scores at EOT than at baseline (Table 4). For instance, patients who had partial or complete responses to chemotherapy scored at least 10 points better on the FACT-G total score at EOT than at baseline, compared with an 8 and 13-point decline for patients who were stable or had cancer progression, respectively (P 0.003). No significant difference was found in terms of changes on the ECOG PS, IADL, MMSE, GDS, MNA, Charlson s index, CIRS-G, or other FACT-G subscale scores. DISCUSSION This study was limited by the small sample size and the short follow-up period (the median follow-up for 37 study patients was 130 days) due to its pilot nature. To our knowledge, this study is the first to prospectively and empirically document the changes in physical function, mental health, and QOL among older patients undergoing cancer chemotherapy. The results of the current study revealed that cancer patients aged 70 years and older who were treated at one academic tertiary cancer center experienced deteriorations in functional and emotional measurements after receiving chemotherapy. The deterioration was greater among patients who experienced severe side effects from chemotherapy than those who did not, and among patients with tumor progression or stable disease than among those with partial or complete treatment responses. However, other aspects of function and mental health, as well as comorbidity and nutrition, were generally preserved. In addition, there was evidence of improved QOL in social well-being among patients who experienced severe chemotoxicities and in function and emotion among patients who had partial or complete treatment responses.
6 1112 CANCER February 15, 2003 / Volume 97 / Number 4 TABLE 4 Significant Changes in FACT-G Scores among Patients with Different Tumor Responses Tumor responses FACT-G Progression (n 7) Stable (n 9) Partial response (n 8) Complete response (n 3) Adjuvant (n 7) P value Total score Emotion Function FACT-G: Functional Assessment of Cancer Therapy-General. Older cancer patients in this study showed a significant decline in functional measurement after receiving chemotherapy, as indicated by changes in IADL scores and in the physical and functional subscale scores of the FACT-G QOL instrument between baseline and EOT. Meanwhile, this group of patients also displayed a worse score on postchemotherapy GDS. Overall, greater than one-half of the patients experienced some level of decline in terms of functional and/or emotional measurements after treatment. Previous literature that evaluated treatment effect on these aspects of older cancer patients is sparse and few used standard instruments. 17,18 A recent study comprising younger patients also found that women who received chemotherapy for breast carcinoma reported lower physical well-being on the FACT-G scale than those who did not receive chemotherapy. 33 In the current study, ECOG PS scores also declined but did not achieve a significant level as other functional instruments. This most likely was because the ECOG PS, which measures a more basic function, was not as sensitive as the IADL and other scales. The IADL and other scales measure higher levels of functional activities (e.g., transportation and meal preparation) that could be affected by chemotherapy or its toxicity at a much earlier stage of disease treatment. The worsening depressive mood after chemotherapy has not been reported before. For the most part, the GDS scores at EOT were still below the usual cutoff score of 5 on the GDS scale, which measures clinically significant depression. However, similar items on the emotional well-being subscale of the FACT-G showed no significant change after chemotherapy. In fact, the items that patients most often cited on the GDS after treatment were relevant to decreasing activities and low energy level, most likely due to the treatment itself. It is not clear to what extent this kind of functional and mood status change was due to the cancer itself or to the impact of the side effects experienced by patients during treatment. Further analysis revealed that the declines in function and depression measurements were not significantly different among patients who had different tumor responses to the chemotherapy treatment. However, for the FACT-G total score and the emotional and functional subscale scores, patients with stable disease or progression of tumor showed worse scores at EOT than at baseline. Conversely, patients with partial or complete responses achieved better scores at EOT than at baseline. Other investigators have demonstrated the impact of various side effects that older cancer patients experienced when they received chemotherapy for different cancers, such as nausea, emesis, neutropenia, and neurotoxicity. 17,18 Modestly increased hospitalization rates with increasing age due to complications of adjuvant chemotherapy were observed in Stage III colon carcinoma patients age 65 years during a 6-month interval. 6 In the current study, an incidence rate of greater than 50% was observed for severe treatment side effects, defined as Grade 4 hematologic and Grade 3 4 nonhematologic toxicities. This study was not designed to compare the CGA changes among older cancer patients who received chemotherapy with a control group of patients who did not receive treatment. Instead, the available data allowed us to compare the differences in CGA changes between patients who experienced severe chemotoxicities and those who did not. Not surprisingly, the occurrence of treatment-related severe toxicities contributed to the deterioration in measurements of functional and mood status in this group of patients. Although patients without severe chemotoxicities showed a slight improvement in ECOG PS scores, those experiencing chemotoxicities became more dependent. This was more evident when comparing the IADL scores between these two groups, i.e., there was a 17-fold difference in the score changes. A similar trend was also noted for GDS scores between the these two groups. Do the above data suggest that older cancer patients are not able to tolerate chemotherapy? Does chemotherapy do more harm than good to this patient population, who can still benefit from the treatment
7 Chemotherapy in Older Patients/Chen et al but who are usually undertreated? Although greater than 80% of the study participants had received previous cancer treatment (surgery, chemotherapy, radiation, and other therapy), the baseline CGA scores showed that they were, in general, functionally independent and mentally sound with good nutrition and QOL. Declines notwithstanding, the changes in CGA scores observed in this study were small in magnitude clinically. Caution should be taken when extrapolating statistically significant findings to clinical meaningful interpretations. In addition, these results represented patients status at the end of chemotherapy, probably the highest level of repercussion of that treatment. It is likely that if they were followed for a longer period of time after the treatment, some aspects of physical and mental health could eventually return to prechemotherapy baseline levels. Equally important is the fact that patients nutrition, comorbidity, and other QOL levels were largely preserved and that the majority of patients were retained a fairly normal level of basic function (ECOG PS) and cognition (MMSE) during treatment. Comorbidity, as measured by the Charlson index and the CIRS-G scale in this study, was not uncommon among the study patients. However, it did not seem to be affected significantly by the treatment. The reasons for the little change in comorbidity scales could be that the treatment per se did not lead to additional comorbid conditions or the conditions, if any, did not develop within the follow-up period. Furthermore, although patients with severe chemotoxicities encountered more declines in terms of functional and emotional measurements than other patients, they also achieved more gains in social/family wellbeing and QOL. A reasonable explanation could be that these patients received more social support from family and friends when they were suffering from more severe and detrimental toxic effects. More data from studies like this one are still needed to provide definite answers to the above questions. Nevertheless, the current study does not support the notion that older patients are not able to tolerate cancer chemotherapy. Patients in this study received a fairly high level of the planned doses (95% dose intensity on average). Older age does not necessarily lead to more severe toxic effects from chemotherapy, compared with younger patients, nor does age-associated comorbidity. 17,19,20 In our detailed analysis of the predictive power of patients characteristics on toxicity from chemotherapy, baseline functional, emotional, and mental status did not correlate significantly with the occurrence of severe chemotherapy-related toxicity in older cancer patients. 20 Future research in this field should use prospective designs to follow a larger sample and a more diverse geriatric oncology population receiving various chemotherapeutic regimens. The outcome measurements need to be comprehensive enough to capture clinical, psychological, social, and QOL dimensions with valid instruments. They also need to take into account potential confounding factors (e.g., potential interaction effects between chemotherapy and other therapies) that could affect the treatment efficacy of older people. A strength of this study is that it encompasses nontraditional end points in outcome research of cancer treatment. Recognizing these treatment-related changes can help oncologists and other health care providers to carefully monitor possible deteriorations in functional and mood status among older cancer patients as a result of chemotherapy treatment. Efforts should be made to identify older cancer patients who may be at increased risk of developing treatment toxicities and to establish patient profiles that can predict and eventually prevent such incidents. 20 This information can also help older patients and their families to anticipate and prepare for the changes and the inconvenience that chemotherapy may cause. It is necessary to pay more attention to providing adequate supportive care to this patient group through antidotes to drug toxicity such as hematopoietic growth factors, prophylactic antibiotics, timely management of complications 14 and, if necessary, early psychiatric intervention for depression. Another important issue is to increase physicians knowledge about the efficacy of treating older cancer patients with chemotherapy and their tolerability to such treatment. As a result, patterns of cancer care in older patients would become more optimal through better utilization of the adequate treatment options that are currently available. A recent survey revealed that oncologists perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials were multidimensional. 13 Some of the most important barriers include concerns of treatment toxicity, and the significant comorbid conditions that older patients have, which are not excluded by the protocol but may affect how they would respond to treatment. Providing physicians with educational materials concerning treatment toxicity in older people was suggested by oncologists as one of the most effective interventions for improving the accrual of older patients to trials. Finally, it is equally important to educate older patients and their families of the myths regarding chemotherapy because they may choose not to accept chemotherapy based on the misperception that they would experience greater toxic effects than younger patients or that they would tolerate the treatment poorly. Older cancer patients undergoing chemotherapy may experience toxicity but generally are able to tolerate
8 1114 CANCER February 15, 2003 / Volume 97 / Number 4 it with limited impact on independence, comorbidity and QOL levels. Comprehensive geriatric asssessment is very useful in detecting treatment-related changes in geriatric oncology patients and should be incorporated into clinical outcome analysis. 22,34 It is important to recognize and monitor these changes during cancer treatment. Future research needs to identify older people who are most susceptible to treatment toxicity and to subsequent functional and emotional status change. In addition, we should find ways to provide optimal cancer treatment with adequate supportive care as well as treatment modification strategies. REFERENCES 1. Yancik R, Ries LA. Aging and cancer in America. Hematol Oncol Clin North Am. 2000;14: Damhuis RAM, Blom JHM. The influence of age on treatment choice and survival in 735 patients with renal carcinoma. Br J Urol. 1995;75: Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer. 1993;72: Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA. 1987; 257: Newschaffer CJ, Penberthy LE, Desch CE, Retchin SM, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med. 1996;156: Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93: Silliman RA, Guadagnoli E, Weitberg AB, Mor V. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol Med Sci. 1989;44: Goodwin JS. Factors affecting the diagnosis and treatment of older persons with cancer. In: Balducci L, Lyman GH, Ershler WB. Comprehensive geriatric oncology. London: Harwood, 1998: Samet JM, Junt WC, Key C, Humble C, Goodwin JS. Choices of cancer therapy varies with age of patient. JAMA. 1986;255: Turner NJ, Haward RA, Mulley GP, Selby PJ. Cancer in old age is it inadequately investigated and treated? BMJ. 1999;319: Satariano WA. Comorbidity and functional status in older women with breast cancer: implications for screening, treatment, and prognosis. J Gerontol. 1992;47: Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285: Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 2002; 95: Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer. 1997;80: Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol. 1996;14: Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19: Feliu J, Gomez LL, Madronal C, et al. Gemcitabin plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer. 1999;86: The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91: Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345: Extermann M, Chen H, Cantor AB, et al. Predictors of tolerance to chemotherapy in older patients: a prospective pilot study. Eur J Cancer. 2002;38: Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol ;16: Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20: Balducci L, Extermann M, Carreca I. Management of breast cancer in the older woman. Cancer Control. 2001;8: Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis. 1960;11: Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull. 1988;24: , Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12: Sheikh JJ, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL. Clinical gerontology: a guide to assessment and intervention. New York, NY: Haworth Press, 1986: Guigoz Y, Vellas B, Garry PJ. Mini nutritional assessment: a practical assessment tool for grading the nutritional state of elderly patients. Facts Res Gerontol. 1994;4(Suppl 2): Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40: Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res. 1992;41: Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11: Hryniuk WM, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4: Arora NK, Gustafson DH, Hawkins RP, et al. Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma. A prospective study. Cancer. 2001;92: Extermann M, Aapro MS. Assessment of the older cancer patient. Hematol Oncol Clin North Am. 2000;14:63 77.
Geriatric screening tools in older patients with cancer
Geriatric screening tools in older patients with cancer Pr. Elena Paillaud Henri Mondor hospital, Créteil, France University Paris-Est Créteil CONFLICT OF INTEREST DISCLOSURE I have the following potential
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationAssessing older patients with hematological malignancies
Assessing older patients with hematological malignancies Alfonso J. Cruz Jentoft Servicio de Geriatría Hospital Universitario Ramón y Cajal Madrid, Spain Is old = frail? 45 days old 2,000 years old 4,600
More informationRehabilitation of the Older Cancer Patient. Lodovico Balducci, M.D. Moffitt Cancer Center Tampa, Florida
Rehabilitation of the Older Cancer Patient Lodovico Balducci, M.D. Moffitt Cancer Center Tampa, Florida Rehabilitation of the older cancer patient Is cancer treatment effective in older individuals? Chronologic
More informationCancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka
Cancer Treatment in the Elderly Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka Patients 65 and older are the fastest growing segment of the US population By 2030, it will comprise
More informationGeriatric Assessment to Improve Outcomes for Older Adults with Cancer
Geriatric Assessment to Improve Outcomes for Older Adults with Cancer Allison Magnuson, DO Assistant Professor of Medicine University of Rochester Medical Center Objectives Appreciate the demographics
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationThe Role that Geriatricians Can Play in the Care of Older Patients with Cancer Across the Care Continuum
The Role that Geriatricians Can Play in the Care of Older Patients with Cancer Across the Care Continuum Holly M. Holmes, MD, MS Associate Professor and Division Director Geriatric and Palliative Medicine
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationWhat is New in Geriatric Oncology: The Medical Oncology Perspective. Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope
What is New in Geriatric Oncology: The Medical Oncology Perspective Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope Cancer Incidence in the U.S. Between 2010 and 2030, cancer incidence
More informationYuh-Min Chen, MD, PhD; Reury-Perng Perng, MD, PhD; Jen-Fu Shih, MD; Chun-Ming Tsai, MD; and Jacqueline Whang-Peng, MD
Chemotherapy for Non-small Cell Lung Cancer in Elderly * Yuh-Min Chen, MD, PhD; Reury-Perng Perng, MD, PhD; Jen-Fu Shih, MD; Chun-Ming Tsai, MD; and Jacqueline Whang-Peng, MD Study objective: To determine
More information2012 AAHPM & HPNA Annual Assembly
in the Last 2 Weeks of Life: When is it Appropriate? When is it Not Appropriate? Disclosure No relevant financial relationships to disclose AAHPM SIG Presentation Participants Eric Prommer, MD, FAAHPM
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationCaring for the Older Patient with Cancer in the Primary Care Setting. Janine Overcash, PhD, GNP-BC. University of South Florida
Caring for the Older Patient with Cancer in the Primary Care Setting Janine Overcash, PhD, GNP-BC University of South Florida jovercas@health.usf.edu (813) 727-7277 cell phone Objectives At the end of
More informationAuthor Block M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland University of Texas M.D. Anderson Cancer Ce
Survey of disease and treatment-related t t related symptoms in outpatients with invasive i cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study, Abst # 9619) Michael J. Fisch,
More informationDr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India
IMPORTANCE OF COMPREHENSIVE GERIATRIC ASSESSMENT IN CANCER IN ELDERLY AN INDIAN PERSPECTIVE Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India INTRODUCTION - Cancer in
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationComprehensive Geriatric Assesment (CGA) In Older Patients with Malignant Hemopathies
BHSSeminar#7 Generalskills Comprehensive Geriatric Assesment (CGA) In Older Patients with Malignant Hemopathies Prof.&&&Dominique&&BRON& Inst.&J.&Bordet&&7&ULB& 24th&of&May&2014& 1 WHY WHEN HOW WhyCGA?!
More informationTHE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE
THE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE Washington University grants permission to use and reproduce the The Importance of Comorbidity
More informationTREATMENT CONSIDERATIONS IN CLL/SLL AND FL. June 6, 2018
TREATMENT CONSIDERATIONS IN CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Discuss key considerations that influence patient outcomes Highlight the importance of patients quality
More informationMultidimensional fatigue and its correlates in hospitalized advanced cancer patients
Chapter 5 Multidimensional fatigue and its correlates in hospitalized advanced cancer patients Michael Echtelda,b Saskia Teunissenc Jan Passchierb Susanne Claessena, Ronald de Wita Karin van der Rijta
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationAdjuvant Chemotherapy in the Elderly: Whom to Treat, What Regimen? Susan Burdette-Radoux, Hyman B. Muss
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer Adjuvant Chemotherapy in the Elderly: Whom to Treat,
More informationAre the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Clinical practice guidelines Definition > Systemically developed statements
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationUpper-Body Strength and Breast Cancer: A Comparison of the Effects of Age and Disease. William A. Satariano and David R. Ragland
Journal of Gerontology: MEDICAL SCIENCES 1996, Vol. 51A, No. 5, M215-M219 Copyright 1996 by The Geronlological Society of America Upper-Body Strength and Breast Cancer: A Comparison of the Effects of Age
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
More informationRecommendations NCCN, SIOG, SoFOG, etc.
Recommendations NCCN, SIOG, SoFOG, etc. Etienne Brain, MD, PhD Medical Oncology HÔPITAL RENÉ HUGUENIN Au 1 er janvier 2010, le Centre René Huguenin devient l Hôpital René Huguenin, un établissement de
More informationPaul Calabresi Award. From suboptimal to optimal treatment in older patients with cancer. Pierre Soubeyran, MD, PhD
Paul Calabresi Award From suboptimal to optimal treatment in older patients with cancer Pierre Soubeyran, MD, PhD Institut Bergonié, Université Bordeaux Segalen Health status-adapted cancer care Balance
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationAdvances in chemotherapy for HER2-negative metastatic breast cancer
Review Article Page 1 of 5 Advances in chemotherapy for HER2-negative metastatic breast cancer Hirofumi Mukai, Mayuko Ito Department of Breast and Medical Oncology, National Cancer Center Hospital East,
More informationImpact of breast cancer survivorship on quality of life in older women
Critical Reviews in Oncology/Hematology 62 (2007) 84 91 Impact of breast cancer survivorship on quality of life in older women Contents Claire Robb a,, William E. Haley b, Lodovico Balducci c, Martine
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationPostoperative Mortality in Lung Cancer Patients
Review Postoperative Mortality in Lung Cancer Patients Kanji Nagai, MD, Junji Yoshida, MD, and Mitsuyo Nishimura, MD Surgery for lung cancer frequently results in serious life-threatening complications,
More informationPhysician Factors in the Timing of Cancer Patient Referral to Hospice Palliative Care
2733 Physician Factors in the Timing of Cancer Patient Referral to Hospice Palliative Care Elizabeth B. Lamont, M.D., M.S. 1 Nicholas A. Christakis, M.D., Ph.D., M.P.H. 2 1 Sections of General Medicine
More informationAdverse side effects associated to metronomic chemotherapy
Adverse side effects associated to metronomic chemotherapy Elisabetta Munzone, MD Division of Medical Senology Istituto Europeo di Oncologia Milano, Italy LDM: the optimal biological dose Although there
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationClinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients
https://doi.org/10.1007/s10147-018-01385-8 ORIGINAL ARTICLE Clinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients Satoko Ito 1 Haruyuki Ito 2 Noriyuki
More informationAuthor(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3)
Title Trends in chemotherapy for elderly non-small-cell lung cancer. Author(s) Kim, Young Hak; Yoh, Kiyotaka; Niho Ohmatsu, Hironobu; Kubota, Kaoru; N Citation Respiratory medicine (2010), 104(3) Issue
More informationCARDIOVASCULAR CONSIDERATIONS IN THE GERIATRIC PATIENT WITH CANCER
CARDIOVASCULAR CONSIDERATIONS IN THE GERIATRIC PATIENT WITH CANCER MARTINE EXTERMANN, MD, PHD MOFFITT CANCER CENTER, UNIVERSITY OF SOUTH FLORIDA TAMPA, FL, USA JEOPARDY CATEGORIES Age as a risk factor
More informationLife expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients
Critical Reviews in Oncology/Hematology 37 (2001) 147 152 www.elsevier.com/locate/critrevonc Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients L. Repetto
More informationThe. JOHN GLASPY, a,e LAURENT DEGOS, b,e MARIO DICATO, c,e GEORGE D. DEMETRI d,e LEARNING OBJECTIVES ABSTRACT
The Oncologist Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials JOHN
More informationQuality of Life During Androgen Deprivation Therapy for Prostate Cancer: A Longitudinal, Controlled Comparison
Quality of Life During Androgen Deprivation Therapy for Prostate Cancer: A Longitudinal, Controlled Comparison Yasmin Asvat Brian Gonzalez Morgan Lee Pamela Reiersen Charissa Hicks Paul B. Jacobsen H.
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationA. Cover Page: Grant ID #: NCCN and Pfizer Independent Grants for Learning & Change Metastatic Breast Cancer
A. Cover Page: Project Title: Improving the approach to and management of the older metastatic breast cancer patient via a provider didactic intervention Grant ID #: NCCN and Pfizer Independent Grants
More informationLow-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
Med Oncol (2014) 31:870 DOI 10.1007/s12032-014-0870-2 ORIGINAL PAPER Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer Jasmine Miger Annika Holmqvist Xiao-Feng Sun Maria Albertsson
More informationEvaluation of Preventive Care Program for Cognitive Function Decline among Community-dwelling Frail Elderly People A Pilot Study
Journal of Japan Academy of Community Health Nursing Vol. 9, No. 2, pp. 87 92, 2007 Evaluation of Preventive Care Program for Cognitive Function Decline among Community-dwelling Frail Elderly People A
More information22th March Endpoints and their relevance to older people: Cancer and Palliative Care and work of EORTC. Ulrich Wedding
22th March 2012 Endpoints and their relevance to older people: Cancer and Palliative Care and work of EORTC Elderly Task Force EORTC, Brussels University of Jena, Germany Department of Palliative Care
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationSupplementary Online Content
Supplementary Online Content Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. doi:10.1001/jama.2016.21038 Additional
More informationIntegrating Geriatrics into Oncology Care
Integrating Geriatrics into Oncology Care William Dale, MD, PhD Chief, Geriatrics & Palliative Medicine Director, Specialized Oncology Care & Research in the Elderly (SOCARE) Clinic University of Chicago
More informationBOTH the incidence and mortality of cancer increase
Journal of Gerontology: MEDICAL SCIENCES 2008, Vol. 63A, No. 5, 518 522 Copyright 2008 by The Gerontological Society of America Usefulness of Frailty Markers in the Assessment of the Health and Functional
More informationQuality-of-Life Assessment in Palliative Care
Alexei Smirnov (Russian, 1961-), Holiday, 1995. Oil on canvas, 50x70 cm. Quality-of-Life Assessment in Palliative Care Susan C. McMillan, PhD, RN, FAAN Background: Understanding the effects of cancer on
More informationDetection and evaluation of the role of sarcopenia in elderly patients with cancer treated with chemotherapy. ONCOSARCO Project. Preliminary results
Detection and evaluation of the role of sarcopenia in elderly patients with cancer treated with chemotherapy. ONCOSARCO Project. Preliminary results Maria José Molina Garrido, JA Santiago-Crespo, MM Muñoz-Sánchez,
More informationGERIATRIC ONCOLOGY. An Introduction. Dr Lissandra Dal Lago, MD, PhD Dr Noam Pondé, MD Institut Jules Bordet, Brussels, Belgium
An Introduction Dr Lissandra Dal Lago, MD, PhD Dr Noam Pondé, MD Institut Jules Bordet, Brussels, Belgium PLAN OF MODULE Demographics of cancer and aging Chronological age vs. functional age The aging
More informationVariations in Patients Self-Report of Pain by Treatment Setting
444 Journal of Pain and Symptom Management Vol. 25 No. 5 May 2003 Original Article Variations in Patients Self-Report of Pain by Treatment Setting Cielito C. Reyes-Gibby, DrPH, Linda L. McCrory, RN, and
More informationComorbidities and cancer Applications to non small cell lung cancer
Comorbidities and cancer Applications to non small cell lung cancer Pr A. Vergnenègre Dr H. Le Caer CHU Limoges CH Draguignan 1 Comorbidities and cancer Why? 2 Epidemiology elderly among lung cancer 2010-2014
More informationApproach to Decision Making in Older Patients with Cancer
Approach to Decision Making in Older Patients with Cancer Toni Pacioles, MD Assistant Professor Hematology and Medical Oncology Joan C. Edwards School of Medicine at Marshall University Overview Cancer
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationNon-small cell lung cancer (NSCLC) accounts for 80% of
ORIGINAL ARTICLE Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience Athanasios G.
More informationRESEARCH ARTICLE. Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry
DOI:http://dx.doi.org/.734/APJCP.22.3..568 RESEARCH ARTICLE Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry Mai Utada *, Yuko
More informationDifferences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study
Cataldo et al. BMC Cancer 2013, 13:6 RESEARCH ARTICLE Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study Open Access Janine K Cataldo 1, Steven
More informationPatient Experience Research in Malignant Hematology: describing the lived experience of illness with acute myeloid leukemia
Patient Experience Research in Malignant Hematology: describing the lived experience of illness with acute myeloid leukemia Thomas W. LeBlanc, MD, MA, MHS, FAAHPM Associate Professor of Medicine Division
More informationLung cancer is the most common cause of cancer-related
GUIDELINES Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline Susanna Cheng, MD,* William K. Evans, MD, Denise Stys-Norman, PgDip, Frances A. Shepherd, MD, and
More informationPanel Two: Evidence for Use of Maintenance Therapy
Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued
More informationCancer Care in the Veterans Health Administration
Cancer Care in the Veterans Health Administration Michael J Kelley, MD National Program Director for Oncology Department of Veterans Affairs Professor of Medicine Duke University Medical Center Chief,
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy
More informationThe Long-term Prognosis of Delirium
The Long-term Prognosis of Jane McCusker, MD, DrPH, Professor, Epidemiology and Biostatistics, McGill University; Head, Clinical Epidemiology and Community Studies, St. Mary s Hospital, Montreal, QC. Nine
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationASCO Advanced Course
EVALTUATION OF AGING: PHYSIOLOGIC AGE LODOVICO BALDUCCI M.D. H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE NCCN GUIDELINES SOME FORM OF GERIATRIC ASSESSMENT FOR INDIVIDUALS AGED 70+ ADJUSTMENT OF
More informationBleomycin, Etoposide and CISplatin (BEP) Therapy
Bleomycin, Etoposide and CISplatin (BEP) Therapy INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Adjuvant treatment of high risk (vascular invasion C62 00300a carcinoma) stage 1 nonseminoma germ cell
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationSAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team
SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationEarly Integration of Palliative Care
Early Integration of Palliative Care Dr. Camilla Zimmermann Head, Palliative Care Program University Health Network Toronto November 1, 2014 www.fpon.ca Early Integration of Palliative Care: Evidence and
More informationThe Clinical Research E-News
Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized
More informationOutcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions
Outcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions AA Moccia, S Gobba, A Conconi, S Diem, L Cascione, K Aprile von Hohenstaufen, W Gulden Sala, A Stathis, F Hitz, G Pinotti,
More informationThe Clinical Research E-News
Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationDoes aging enhance the susceptibility of older individuals to environmental carcinogens?
Chapter 1 EPIDEMIOLOGY OF CANCER AND AGING Lodovico Balducci and Matti Aapro Lodovico Balducci, Program Leader, Senior Adult Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa,
More informationProfessor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationThe Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly
ORIGINAL ARTICLE Korean J Intern Med 2016;31:594-600 The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly Hee-Won Jung 1,2, Hyun-Jung
More informationIntegrating Palliative and Oncology Care in Patients with Advanced Cancer
Integrating Palliative and Oncology Care in Patients with Advanced Cancer Jennifer Temel, MD Massachusetts General Hospital Cancer Center Director, Cancer Outcomes Research Overview 1. Why should we be
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationDATA ELEMENTS NEEDED FOR QUALITY ASSESSMENT COPYRIGHT NOTICE
DATA ELEMENTS NEEDED FOR QUALITY ASSESSMENT COPYRIGHT NOTICE Washington University grants permission to use and reproduce the Data Elements Needed for Quality Assessment exactly as it appears in the PDF
More informationMonitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio )
Monitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio ) Heinz Ludwig Wilhelminen Cancer Research Institute c/o I
More information